{"entity":{"id":"adc-side-effects-breast","kind":"term","name":"Living with an antibody-drug conjugate: diarrhoea, blood counts, eyes and lungs","aka":["ADC side effects"],"tldr":"The antibody-drug conjugates used in triple-negative breast cancer carry chemotherapy into the cancer but still cause chemotherapy-like effects: sacituzumab govitecan mainly low white cells and diarrhoea, datopotamab deruxtecan mouth soreness, eye problems and rarely lung inflammation, trastuzumab deruxtecan lung inflammation and sickness. Each has a threshold for ringing the 24-hour line.","summary":"Macmillan says sacituzumab govitecan is given on days 1 and 8 of a 21-day cycle, that it can cause severe diarrhoea, and to contact the hospital straight away on the 24-hour number for diarrhoea 4 or more times in a day, diarrhoea at night, or anti-diarrhoea drugs not working within 24 hours, as well as for a temperature above 37.5 C or below 36 C. Breast Cancer Now uses 3 or more times in 24 hours and says growth factor injections are sometimes recommended to protect white cells. The Datroway label requires eye examinations and lists keratitis; the Enhertu label carries a boxed warning for interstitial lung disease, and a pooled analysis found 15.4% of people on trastuzumab deruxtecan developed drug-related lung inflammation, most within the first year. This is orientation from public patient pages and guidelines, not advice for your case: your own team's instructions and 24-hour number come first.","asOf":"2026-09-24","links":[{"label":"Macmillan: sacituzumab govitecan","url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/sacituzumab-govitecan"},{"label":"Breast Cancer Now: sacituzumab govitecan (Trodelvy)","url":"https://breastcancernow.org/about-breast-cancer/treatment/targeted-therapy/sacituzumab-govitecan-trodelvy"},{"label":"Macmillan: antibody drug conjugate treatment","url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/antibody-drug-conjugate"},{"label":"Powell et al., pooled analysis of interstitial lung disease in nine trastuzumab deruxtecan studies (ESMO Open 2022)","url":"https://doi.org/10.1016/j.esmoop.2022.100554"},{"label":"Bardia et al., sacituzumab govitecan in metastatic triple-negative breast cancer, ASCENT (NEJM 2021)","url":"https://doi.org/10.1056/NEJMoa2028485"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["sacituzumab-govitecan","datopotamab-deruxtecan","trastuzumab-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":["neutropenia","ild","ocular-toxicity"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Side effects"},"route":"/terms/adc-side-effects-breast/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"term":[{"id":"ild","kind":"term","name":"Interstitial lung disease (ILD) / pneumonitis","route":"/terms/ild/"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/"},{"id":"ocular-toxicity","kind":"term","name":"Ocular toxicity (keratopathy, blurred vision)","route":"/terms/ocular-toxicity/"}]}}